AMERICAN SOCIETY FOR MICROBIOLOGY | Antimicrobial Agents and Chemotherapy®

AUTHOR CORRECTION

Correction for Schmidt-Malan et al., "*In Vitro* Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli"

Suzannah M. Schmidt-Malan,[a] Avisya J. Mishra,[a] Ammara Mushtaq,[a] Cassandra L. Brinkman,[a] Robin Patel[a,b]

[a]Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

[b]Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Volume 62, no. 8, e00533-18, 2018, https://doi.org/10.1128/AAC.00533-18. Isolate IDRL-10579 in Supplemental Table S2 is *Pseudomonas aeruginosa* but was mistakenly reported as *Klebsiella pneumoniae*; the isolate should be listed in Table S2 under *P. aeruginosa* containing a KPC genetic resistance mechanism. Accordingly, in the 1st paragraph of Materials and Methods, of the 177 isolates which are carbapenemase positive, 118 (not 119) are *K. pneumoniae* and 5 (not 4) are *P. aeruginosa*. Also, in Supplemental Table S4, there are 85 (not 86) isolates which are *K. pneumoniae* complex and 2 (not 1) isolates which are *P. aeruginosa*. Revised versions of these two supplemental tables have been posted online.

In addition, the KPC gene-positive section of Table 2 has been revised as shown below due to an error in the cumulative MIC results. Accordingly, in the Results section, in the 1st paragraph of "Carbapenemase gene-positive isolates," 3% (not 5%) of the KPC-positive isolates were susceptible to imipenem, 2% (not 3%) were susceptible to cefepime, 1% (not 2%) were susceptible to ceftriaxone, and 3% (not 4%) were susceptible to ceftolozane-tazobactam. In the 3rd paragraph of the Discussion section, 95% (not 93%) of the KPC-positive isolates were resistant to imipenem alone.

Citation Schmidt-Malan SM, Mishra AJ, Mushtaq A, Brinkman CL, Patel R. 2019. Correction for Schmidt-Malan et al., "*In vitro* activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli." Antimicrob Agents Chemother 63:e02563-18. https://doi.org/10.1128/AAC.02563-18.

Copyright © 2019 American Society for Microbiology. All Rights Reserved.

TABLE 2 Cumulative MIC results for NDM, IMP, and KPC gene-positive isolates for all antimicrobial agents tested[a]

Type of isolate and drug	No. of isolates (cumulative %) inhibited at specified concn (μg/ml)																		MIC_{50} (μg/ml)	MIC_{90} (μg/ml)	% S	% I	% R
	0.0018	0.0037	0.008	0.015	0.03	0.06	0.125	0.25	0.5	1	2	4	8	16	32	64	128	>128					
NDM gene-positive isolates (n = 31)																							
Imipenem						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.2)	4 (16.1)	10 (48.4)	9 (77.4)	6 (96.7)	1 (100.0)	32		0[b]	0[b]	100[b]
(4 μg/ml relebactam)																							
Imipenem						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.2)	4 (16.1)	12 (54.8)	7 (77.4)	5 (93.5)	2 (100.0)	32	128	0	0	100
Ertapenem						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.2)	3 (12.9)	9 (41.9)	10 (74.2)	8 (100.0)	128	>128	0	0	100
Meropenem						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (12.9)	4 (25.8)	9 (54.8)	10 (87.1)	4 (100.0)	64	>128	0	0	100
Ceftolozane						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	31 (100.0)	>128	>128	0	0	100
(4 μg/ml tazobactam)																							
Cefepime						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (6.4)	2 (12.9)	27 (100.0)	>128	>128	0	NA	100
Ceftriaxone						0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	31 (100.0)	>128	>128	0	0	100
IMP gene-positive isolates (n = 11)																							
Imipenem					0 (0.0)	1 (9.1)	0 (9.1)	0 (9.1)	0 (9.1)	1 (18.2)	1 (27.3)	3 (54.5)	1 (63.6)	1 (72.7)	0 (72.7)	0 (72.7)	2 (90.9)	1 (100.0)	4	128	18.2[b]	9.1[b]	72.7[b]
(4 μg/ml relebactam)																							
Imipenem					0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)	1 (18.2)	1 (27.3)	2 (45.5)	2 (63.6)	1 (72.7)	0 (72.7)	0 (72.7)	2 (90.9)	1 (100.0)	8	128	18.2	9.0	72.8
Ertapenem					0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (18.2)	1 (27.3)	0 (27.3)	4 (63.6)	0 (63.6)	1 (72.7)	1 (81.8)	2 (100.0)	16	>128	0	0	100
Meropenem					0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)	2 (27.3)	0 (27.3)	0 (27.3)	3 (54.5)	1 (63.6)	1 (72.7)	1 (81.8)	2 (100.0)	0 (100.0)	8	128	27.3	0	72.7
Ceftolozane					0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)	0 (9.1)	0 (9.1)	1 (18.2)	9 (100.0)	>128	>128	0	0	100
(4 μg/ml tazobactam)																							
Cefepime					0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)	2 (27.3)	1 (36.4)	1 (45.5)	0 (45.5)	6 (100.0)	>128	>128	0	NA	91.9
Ceftriaxone					0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)	2 (27.3)	8 (100.0)	>128	>128	0	0	100
KPC gene-positive isolates (n = 110)																							
Imipenem	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	5 (5.4)	15 (19.0)	23 (40.0)	20 (58.2)	21 (77.3)	15 (90.9)	4 (94.5)	1 (95.4)	1 (96.4)	2 (98.2)	1 (99.1)	0 (99.1)	0 (99.1)	1 (100.0)	0.25	1	90.9[b]	3.6[b]	5.4[b]
(4 μg/ml relebactam)																							
Imipenem	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	1 (1.8)	1 (2.7)	3 (5.4)	16 (20.0)	15 (33.6)	20 (51.8)	21 (70.9)	11 (80.9)	7 (87.3)	14 (100.0)	16	>128	2.7	2.7	94.5
Ertapenem	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	0 (1.0)	0 (1.0)	0 (1.0)	2 (1.8)	1 (3.6)	4 (7.3)	9 (15.4)	12 (26.4)	16 (40.9)	20 (59.1)	22 (79.1)	23 (100.0)	64	>128	1.0	1.8	97.2
Meropenem	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	0 (1.0)	0 (1.0)	0 (1.0)	3 (3.6)	3 (6.4)	11 (16.4)	13 (28.2)	13 (40.0)	24 (61.8)	9 (70.0)	3 (72.7)	30 (100.0)	32	>128	3.6	2.7	93.6
Ceftolozane	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	1 (1.8)	1 (2.7)	1 (3.6)	1 (4.5)	5 (9.0)	13 (20.9)	21 (40.0)	37 (73.6)	29 (100.0)	128	>128	2.7	1.0	96.3
(4 μg/ml tazobactam)																							
Cefepime	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	0 (1.0)	0 (1.0)	1 (1.8)	4 (5.4)	7 (11.8)	9 (20.0)	6 (25.4)	9 (33.6)	10 (42.7)	63 (100.0)	>128	>128	1.8	NA	88.2
Ceftriaxone	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	1 (1.8)	0 (1.8)	1 (2.7)	1 (3.6)	0 (3.6)	5 (8.2)	8 (15.4)	93 (100.0)	>128	>128	1.0	1.0	98.2

[a]S, susceptible; I, intermediate; R, resistant; NA, not applicable.

[b]Using imipenem breakpoints.